NIH Restarts Grant Awards: What This Means for Researchers and Institutions
April 1, 2026 · 3 min read
Claire Cummings
Hook
After months of uncertainty and funding delays, the National Institutes of Health (NIH) has officially resumed normal grant-making activities as of March 31, 2026. This comes on the heels of the Office of Management and Budget (OMB) approving fiscal year 2026 spending allocations, signaling a restoration of the biomedical research funding pipeline. For researchers, institutions, and nonprofits, this move ends a period where new NIH awards had plummeted—down 63% compared to recent five-year averages—with wide-reaching effects on labs, hiring, and scientific momentum.
Context
The resumption follows a turbulent period fueled by a government shutdown and subsequent budgetary gridlock. Through mid-fiscal year 2026, NIH had obligated just $5.8 billion—only 15% of its $38 billion budget, and far below the $9 billion distributed by the same time in the prior cycle. During the funding freeze, support was largely limited to existing renewals and extensions. New grants, the lifeblood for many early-career investigators and new initiatives, were effectively on hold.
NIH Director Jayanta Bhattacharya described the restart as a priority moment, promising to roll out delayed awards efficiently while acknowledging recent challenges like staff reductions, leadership vacancies, and administrative bottlenecks. The Biophysical Society has hailed this decision as a “critical step towards restoring funding stability” and has pushed for maximum federal support to avoid jeopardizing U.S. scientific leadership.
Universities and research associations, including the Association of American Medical Colleges (AAMC) and the Association of American Universities, have similarly highlighted the tangible impacts: hiring freezes, stalled PhD admissions, lab layoffs, and disrupted scientific careers. In a landscape already strained by global competition, the ability for the NIH to efficiently reobligate funds is considered crucial to maintaining momentum in biomedical innovation.
Impact
For Researchers and Academic Institutions
The practical effect of the resumed grants will be most immediately felt by principal investigators awaiting notice of award, especially those seeking funds for new projects, postdocs, or hiring. Many labs were forced into a holding pattern, relying on multi-year grants or interim, non-renewable funding just to cover salaries and keep experimental programs alive. Early-career researchers—and those due to start new faculty positions—felt the pinch most acutely, with reports of rescinded offers and deferred start dates due to the funding slump.
Now, NIH expects to prioritize both high-scoring proposals delayed by the budget pause and those addressing key public health challenges. Institutions should soon see an uptick in Notice of Award (NoA) activity, particularly in disciplines most affected by the pause (e.g., life sciences, biomedical engineering, public health).
For Nonprofits and Small Businesses
Many NIH programs—including SBIR/STTR funding—were held up, delaying research and development within biotech startups and translational nonprofits. For organizations relying on steady NIH cycles for cash flow and operations, this has meant strategic disruptions or even temporary shutdowns. With funding restored, these organizations should re-engage lapsed applications, check on updated review dates, and direct inquiries to NIH program officials to clarify timelines.
Action Steps for Grant Seekers Now
- Check Your Status: If you submitted an NIH application or were awaiting notice, log into eRA Commons and contact your program official. Awards that stalled may quickly move now.
- Update Institutional Plans: Departments and sponsored programs offices should revisit hiring and admission strategies, including onboarding deferred postdocs or faculty, now that funding is likely to flow.
- Reconnect with Reviewers: For grants reviewed during the hold, reach out to ascertain new paylines or priority scores.
- Monitor SBIR/STTR Cycles: Small businesses and nonprofits should watch for accelerated cycles as the NIH clears backlogs in these programs.
- Document Disruptions: Keep records of any lost opportunities resulting from the freeze, as agencies and professional associations may seek data to advocate for future budget stability.
Outlook
With the NIH resuming awards, the coming weeks will see a flurry of activity as the agency works through a compressed funding cycle. The major risk now is that the rapid rollout could strain administrative bandwidth, so applicants should be vigilant and responsive to communications from NIH. Looking ahead, this episode highlights the vulnerability of the federal research funding ecosystem to fiscal delays—grant seekers and advocates alike should pay close attention during future budget negotiations to prevent recurrences.
Granted AI helps researchers and organizations track funding opportunities and respond quickly to changes in federal grant cycles.
Sources: